5/26/2016

Azithromycin Injection

Products Affected - Description

- Azithromycin intravenous lyophilized powder for solution for injection, Pfizer, 500 mg, ADD-Vantage vial, 10 count, NDC 00409-0144-11
- Azithromycin intravenous lyophilized powder for solution for injection, Sagent, 500 mg, vial, 10 count, NDC 25021-0112-10

Reason for the Shortage

- Fresenius Kabi had azithromycin on shortage due to increased demand.
- Hospira has azithromycin injection on shortage due to manufacturing delays.
- Sagent has azithromycin injection on shortage due to manufacturing delays.

Available Products

- Zithromax intravenous lyophilized powder for solution for injection, Pfizer, 500 mg, vial, 10 count, NDC 00069-3150-83
- Azithromycin intravenous lyophilized powder for solution for injection, Apotex, 500 mg, vial, 10 count, NDC 60505-6076-04
- Azithromycin intravenous lyophilized powder for solution for injection, Fresenius Kabi, 500 mg, vial, 10 count, NDC 63323-0398-10

Estimated Resupply Dates

- Hospira has azithromycin injection on back order and the company estimates a release date of July 2015.
- Sagent has azithromycin injection on back order and the company estimates a release date of July 2015.

Updated

Updated May 26, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 2, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.